AR128003A1 - PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS - Google Patents
PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMASInfo
- Publication number
- AR128003A1 AR128003A1 ARP220103478A ARP220103478A AR128003A1 AR 128003 A1 AR128003 A1 AR 128003A1 AR P220103478 A ARP220103478 A AR P220103478A AR P220103478 A ARP220103478 A AR P220103478A AR 128003 A1 AR128003 A1 AR 128003A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- acid sequence
- idua
- iduronidase
- enzymes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291283P | 2021-12-17 | 2021-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128003A1 true AR128003A1 (es) | 2024-03-20 |
Family
ID=85175822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103478A AR128003A1 (es) | 2021-12-17 | 2022-12-16 | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250136963A1 (https=) |
| EP (1) | EP4448746A1 (https=) |
| JP (1) | JP2024546129A (https=) |
| KR (1) | KR20240119118A (https=) |
| CN (1) | CN118401660A (https=) |
| AR (1) | AR128003A1 (https=) |
| AU (1) | AU2022415476A1 (https=) |
| CA (1) | CA3241240A1 (https=) |
| IL (1) | IL313553A (https=) |
| MX (1) | MX2024007319A (https=) |
| TW (1) | TW202340459A (https=) |
| WO (1) | WO2023114485A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180185495A1 (en) * | 2014-11-10 | 2018-07-05 | Alexion Pharmaceuticals, Inc. | Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| WO2018152285A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| WO2019246071A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| WO2021158986A1 (en) * | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
-
2022
- 2022-12-16 AU AU2022415476A patent/AU2022415476A1/en active Pending
- 2022-12-16 CA CA3241240A patent/CA3241240A1/en active Pending
- 2022-12-16 IL IL313553A patent/IL313553A/en unknown
- 2022-12-16 US US18/719,958 patent/US20250136963A1/en active Pending
- 2022-12-16 KR KR1020247022697A patent/KR20240119118A/ko active Pending
- 2022-12-16 JP JP2024534711A patent/JP2024546129A/ja active Pending
- 2022-12-16 CN CN202280083088.0A patent/CN118401660A/zh active Pending
- 2022-12-16 MX MX2024007319A patent/MX2024007319A/es unknown
- 2022-12-16 WO PCT/US2022/053196 patent/WO2023114485A1/en not_active Ceased
- 2022-12-16 TW TW111148472A patent/TW202340459A/zh unknown
- 2022-12-16 AR ARP220103478A patent/AR128003A1/es unknown
- 2022-12-16 EP EP22854477.1A patent/EP4448746A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024546129A (ja) | 2024-12-17 |
| US20250136963A1 (en) | 2025-05-01 |
| TW202340459A (zh) | 2023-10-16 |
| AU2022415476A1 (en) | 2024-07-04 |
| KR20240119118A (ko) | 2024-08-06 |
| WO2023114485A1 (en) | 2023-06-22 |
| MX2024007319A (es) | 2024-07-22 |
| EP4448746A1 (en) | 2024-10-23 |
| CN118401660A (zh) | 2024-07-26 |
| IL313553A (en) | 2024-08-01 |
| CA3241240A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| de Lencastre Novaes et al. | Stability, purification, and applications of bromelain: A review | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| JP5690785B2 (ja) | 改良されたボツリヌス毒素組成物 | |
| ES2592314T3 (es) | Neurotoxinas clostridiales con persistencia modificada | |
| JP2019194251A5 (https=) | ||
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| ES2632470T3 (es) | Proteínas de fusión y métodos para tratar, prevenir o mejorar el dolor | |
| HRP20141125T1 (hr) | Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis | |
| Girdhar et al. | Antimicrobial peptide-based strategies to overcome antimicrobial resistance | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| KR20030009431A (ko) | 신경독의 말초 투여를 통한 동통 처치 방법 | |
| MX2012002216A (es) | Nueva endolisina obpgplys. | |
| AR066199A1 (es) | Metodo para reducir la concentracion del peptido amiloide beta | |
| AR081680A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DEL a N-ACETIL GLUCOSAMINIDASA | |
| ES2371785T3 (es) | Utilización de al menos una neurotoxina botulínica para tratar el dolor causado por los tratamientos terapéuticos del virus del sida. | |
| CO2023014723A2 (es) | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen | |
| ES2911075T3 (es) | Constructos de administración para transcitosis y métodos relacionados | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| AR128003A1 (es) | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS | |
| ES2537579T3 (es) | Preparación que contiene toxina botulínica de tipo A muy purificada derivada de patógeno de botulismo del lactante | |
| CL2009001249A1 (es) | Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia. | |
| BRPI1014631A2 (pt) | peptídeos e seus usos. | |
| JP2021525711A5 (https=) | ||
| MX2022008748A (es) | Administración oral de péptidos. | |
| JPWO2003082315A1 (ja) | 筋緊張亢進疾患治療剤 |